Article
Long-term efficacy and safety of migalastat treatment in Fabry disease: 30-month results from the open-label extension of the randomized, phase 3 ATTRACT study.
Molecular genetics and metabolism - 1 Jan 2000
Feldt-Rasmussen Ulla, Hughes Derralynn, Sunder-Plassmann Gere, Shankar Suma, Nedd Khan, Olivotto Iacopo, Ortiz Damara, Ohashi Toya, Hamazaki Takashi, Skuban Nina, Yu Julie, Barth Jay A, Nicholls Kathleen
Abstract excerpt
Results from the 18-month randomized treatment period of the phase 3 ATTRACT study demonstrated the efficacy and safety of oral migalastat compared with enzyme replacement therapy (ERT) in patients with Fabry disease who previously received ERT. Here, we report data from the subsequent 12-month, migalastat-only, open-label extension (OLE) period. ATTRACT (Study AT1001-012; NCT01218659) was a randomized,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.